Safety and pharmacokinetics of repeat-dose micafungin in young infants

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 1, 2010, Pages 93-99

  Benjamin Jr , D K ^a   Smith, P B ^a   Arrieta, A ^b   Castro, L ^c   Sanchez P J ^d   Kaufman, D ^e   Arnold, L J ^f   Kovanda, L L ^f   Sawamoto, T ^f   Buell, D N ^f   Hope, W W ^g   Walsh, T J ^h  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f Astellas Pharma US Inc   (United States)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CANDIDEMIA; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GESTATIONAL AGE; HUMAN; HYPOKALEMIA; INFANT; INVASIVE CANDIDIASIS; KIDNEY FAILURE; LUNG EDEMA; MALE; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; PATENT DUCTUS ARTERIOSUS; PH; PHLEBITIS; PRIORITY JOURNAL; REPEAT PROCEDURE; RESPIRATORY DISTRESS; SIDE EFFECT; SKIN DISEASE; STEADY STATE; TEMPERATURE; TREATMENT DURATION; VOMITING;

AGE FACTORS; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LIPOPEPTIDES; MALE;

EID: 72849119258     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.200     Document Type: Article

References (31)

1. Benjamin, D.K. Jr., Poole, C., Steinbach, W.J., Rowen, J.L. & Walsh, T.J. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 112, 634-640 (2003).
2. Benjamin, D.K. Jr. et al.; National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 117, 84-92 (2006).
3. Kaufman, D., Boyle, R., Hazen, K.C., Patrie, J.T., Robinson, M. & Donowitz, L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. 345, 1660-1666 (2001).
4. Stoll, B.J. et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110, 285-291 (2002).
5. Benjamin, D.K. Jr., DeLong, E.R., Steinbach, W.J., Cotton, C.M., Walsh, T.J. & Clark, R.H. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 112, 543-547 (2003).
6. Ernst, E.J., Roling, E.E., Petzold, C.R., Keele, D.J. & Klepser, M.E. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-efect studies. Antimicrob. Agents Chemother. 46, 3846-3853 (2002).
7. Messer, S.A., Diekema, D.J., Boyken, L., Tendolkar, S., Hollis, R.J. & Pfaller, M.A. activities of micafungin against 315 invasive clinical isolates of fuconazole-resistant Candida spp. J. Clin. Microbiol. 44, 324-326 (2006).
8. Petraitis, V. et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46, 1857-1869 (2002).
9. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S. & Diekema, D.J. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44, 3533-3538 (2006).
10. Tawara, S. et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44, 57-62 (2000).
11. Dannaoui, E. et al.; yEaSTS Group. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob. Agents Chemother. 52, 778-781 (2008).
12. Pfaller, M.A. et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46, 150-156 (2008).
13. Pfaller, M.A. et al.; Global antifungal Surveillance Group. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the aRTEMIS DISK antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46, 515-521 (2008).
14. Pfaller, M.A. et al.; Global antifungal Surveillance Group. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the aRTEMIS DISK antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46, 842-849 (2008).
15. Takakura, S., Fujihara, N., Saito, T., Kudo, T., Iinuma, Y. & Ichiyama, S. National surveillance of species distribution in blood isolates of Candida species in japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J. Antimicrob. Chemother. 53, 283-289 (2004).
16. Hatano, K., Morishita, Y., Nakai, T. & Ikeda, F. antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J. Antibiot. 55, 219-222 (2002).
17. Hiemenz, J. et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fuconazole versus fuconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother. 49, 1331-1336 (2005).
18. Kuse, E.R. et al.; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369, 1519-1527 (2007).
19. Pappas, P.G. et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45, 883-893 (2007).
20. Seibel, N.L. et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49, 3317-3324 (2005).
21. Queiroz-Telles, F. et al.; Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J. 27, 820-826 (2008).
22. Smith, P.B. et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr. Infect. Dis. J. 28, 412-415 (2009).
23. Mycamine [US Prescribing Information]. astellas Pharma: Deerfeld, IL, 2008.
24. Mycamine [Summary of Product Characteristics]. astellas Pharma: Munich, Germany, 2008.
25. Heresi, G.P. et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J. 25, 1110-1115 (2006).
26. Hope, W.W. et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J. Infect. Dis. 197, 163-171 (2008).
27. Odio, C.M. et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23, 1093-1097 (2004).
28. Groll, A.H., Stergiopoulou, T., Roilides, E. & Walsh, T.J. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin. Investig. Drugs 14, 489-509 (2005).
29. Sirohi, B. et al. a study to determine the safety profle and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 38, 47-51 (2006).
30. Tabata, K., Katashima, M., Kawamura, A., Tanigawara, Y. & Sunagawa, K. Linear pharmacokinetics of micafungin and its active metabolites in japanese pediatric patients with fungal infections. Biol. Pharm. Bull. 29, 1706-1711 (2006).
31. Food and Drug administration. MedDRa: Medical Dictionary for Regulatory activities (2004). accessed 9 august 2008. http://www.meddramsso.com/MSSOWeb/ index.htm